Darunavir Tablets and Selzentry

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Darunavir may increase the blood levels and effects of maraviroc. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. If you have severe kidney disease, you may not be able to use these medications together. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of maraviroc, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of maraviroc (100 mg twice a day) with the potent CYP450 3A4 inhibitor ketoconazole (400 mg once a day) increased the mean maraviroc peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 3.5- and 5-fold, respectively, compared to administration alone. When the same dosage of maraviroc was administered with ritonavir (100 mg twice a day), maraviroc Cmax increased by nearly 1.3-fold and AUC by 2.6-fold. An even greater increase of nearly 5-fold in Cmax and 10-fold in AUC was observed during coadministration of maraviroc and saquinavir/ritonavir (1000 mg/100 mg twice a day). At 300 mg twice a day, mean maraviroc Cmax increased by approximately 2-fold and AUC by 3.6-fold during coadministration with atazanavir (400 mg once a day). When the same dosage of maraviroc was given with atazanavir/ritonavir (300 mg/100 mg once a day), maraviroc Cmax increased by 2.7-fold and AUC increased by nearly 5-fold. During coadministration with lopinavir/ritonavir (400 mg/100 mg twice a day), maraviroc Cmax and AUC increased by 2-fold and 4-fold, respectively. In patients with hepatic impairment, plasma drug concentrations are higher when maraviroc 150 mg is administered with a potent CYP450 3A4 inhibitor than when maraviroc 300 mg (normally recommended dose) is administered without a CYP450 3A4 inhibitor.

CONTRAINDICATED: Patients with severe renal impairment or end-stage renal disease (CrCl
MANAGEMENT: Maraviroc should be administered at a dosage of 150 mg twice daily during coadministration with potent CYP450 3A4 inhibitors, including most protease inhibitors except tipranavir plus ritonavir. This dosage is recommended whether or not a concomitant CYP450 3A4 inducer (e.g., efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) is given. Patients with moderate hepatic impairment who receive 150 mg with a potent CYP450 3A4 inhibitor should be monitored closely for maraviroc-associated adverse events. Maraviroc is contraindicated for use in combination with potent CYP450 3A4 inhibitors in patients with severe renal impairment or end-stage renal disease (CrCl

Darunavir Tablets

Generic Name: darunavir

Brand name: Prezista

Synonyms: Darunavir

What is Darunavir Tablets?

Selzentry

Generic Name: maraviroc

Brand name: Selzentry

Synonyms: n.a.

What is Selzentry?